Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer

Published:2015-11-11 Issue:6 Volume:76 Page:1217-1224
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kurihara Tatsuya,Kogo Mari,Ishii Masakazu,Shimada Ken,Yoneyama Keiichiro,Kitamura Katsuya,Shimizu Shunichi,Yoshida Hitoshi,Kiuchi Yuji

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2887-4.pdf

Reference38 articles.

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

2. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654–663

3. Bramhall SR, Rosemurgy A, Brown PD et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447–3455

4. Heinemann V, Quietzsch D, Gieseler F et al (2006) A phase III trial comparing gemcitabine plus cisplatine compared with gemcitabine alone in advanced pancreatic adenocarcinoma. J Clin Oncol 24:3946–3952

5. Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC;Trends in Cancer;2024-05

2. Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer;2024

3. Влияние токсичности на объем проведения адъювантной химиотерапии;Malignant tumours;2023-11-24

4. Chemotherapy-Induced Neutropenia as a Prognostic Factor in Patients With Advanced Epithelial Ovarian Carcinoma;Cancer Control;2023-04

5. Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin’s Lymphoma;Hematology Reports;2023-02-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3